Isu Abxis Co Ltd
Isu Abxis has a market price of 4235 KRW and a market cap of 171,749,518,710 KRW, with a price-to-book ratio of 1.5 and a price-to-tangible-book ratio of 1.5. The company's enterprise value to EBITDA is 246.74, and its enterprise value to revenue is 2.98. Despite a current ratio of 1.93, the company's liquidity is assessed as low. Profitability metrics show a return on equity of -9.33% and a return on assets of -6.72%, indicating significant underperformance relative to industry norms. The company's operating income of 685,271,740 KRW is modest compared to its revenue of 56,672,366,050 KRW, and it reported a net loss of 10,678,000,440 KRW. The company's revenue is primarily concentrated in domestic and overseas markets, with no disclosed segment breakdown. Its geographic exposure is not specified in the provided data, but the lack of segment details suggests a need for further analysis of revenue concentration. Growth trajectory is mixed, with a free cash flow of -17,170,352,270 KRW and capital expenditure of -11,128,076,830 KRW. The company's operating cash flow of 11,038,341,360 KRW provides some liquidity, but the negative free cash flow indicates ongoing investment in operations. Risk factors include low liquidity and low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.17 suggests a conservative capital structure, but the net loss and negative return on equity highlight financial instability. Recent events include the latest financial filing, which shows a net loss and negative return on equity. No recent transcripts or filings beyond the financial snapshot are provided, limiting insight into management commentary or strategic shifts.
Business. Isu Abxis Co Ltd develops, manufactures, and sells therapeutic antibodies and proteins, including abcertin, pabagal, and clotinap, primarily in domestic and overseas markets.
Classification. Isu Abxis is classified in the Healthcare economic sector under Pharmaceuticals & Medical Research, with a confidence level of 0.92.
- Isu Abxis has a low liquidity rating despite a current ratio of 1.93.
- The company reported a net loss of 10,678,000,440 KRW and negative returns on equity and assets.
- Free cash flow is negative at -17,170,352,270 KRW, indicating ongoing operational investment.
- The company's capital structure is conservative with a debt-to-equity ratio of 0.17.
- No immediate liquidity or dilution flags were detected in the latest filings.
- # RATIONALES
- ```json
- {
- No immediate filing-based liquidity or dilution flags were detected.